Risk of Motor Complications in Early Parkinson’s Disease Patients Treated with Opicapone in the EPSILON study: Effect of Levodopa Dose
Objective: This post-hoc analysis of the EPSILON study evaluated whether levodopa dose (<400mg/day vs. ≥400mg/day) and opicapone (OPC) timing (at double-blind [DB] or open-label extension…Timing And Type Of Adverse Events Following Long-Term Treatment With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) Infusion – Data From The ELEGANCE Interim Analysis
Objective: To evaluate the type and timing of occurrence of treatment-emergent adverse events (AEs) in people with advanced Parkinson’s disease (PD) following up to one…The efficacy and safety of continuous subcutaneous infusion therapy with foslevodopa/foscarbidopa
Objective: To clarify the actual status of CSCI therapy, cases in which CSCI therapy was started at our hospital were investigated. Background: Continuous subcutaneous infusion…Effect of Opicapone on Sleep-Related Complaints and Non-Motor Burden in Parkinson’s Patients: A Post-Hoc Analysis of the OASIS Trial
Objective: To assess the effect of opicapone (OPC) on different sleep complaints and non-motor symptoms (NMS) in fluctuating Parkinson’s disease (PD) patients with sleep disturbances.…Patient And Clinician Perceptions Of Disease Improvement With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) In Advanced Parkinson’s – Data From The ELEGANCE Interim Analysis
Objective: To evaluate clinicians’ and patients’ views of the level of improvement in Parkinson’s disease (PD) achieved following up to two years of treatment with…Levodopa response in pathology-confirmed Parkinson’s Disease, Multiple System Atrophy and Progressive Supranuclear Palsy
Objective: to describe the rate of levodopa response, phenotypical characteristics, prognostic implications and pathological features in a large cohort of patients with pathology-confirmed Parkinson’s disease…A Phase I Study of TR-012001, a Nasal Levodopa, in Healthy Adult Japanese Male Subjects
Objective: To investigate the safety, tolerability, and pharmacokinetics of TR-012001, a nasal levodopa (LD), in healthy Japanese adult men with and without premedication with dopa…Three-Year Single-Center Experience with Levodopa–Entacapone–Carbidopa Intestinal Gel in Advanced Parkinson’s Disease
Objective: To evaluate the efficacy of Levodopa-Entacapone-Carbidopa Intestinal Gel (LECIG) in advanced Parkinson’s Disease (APD). Background: LECIG infusion has been available in Romania since 2021.…Trends in U.S. Drug Use Among Hospitalized Parkinson’s Patients Experiencing Delirium
Objective: To examine drug use trends among hospitalized Parkinson’s disease (PD) patients in the U.S. and to assess the association between PD medications and delirium.…A Proof-of-Concept Study of TR-012001, a Nasal Levodopa, in Patients With Parkinson’s Disease With OFF Episodes, Without Dopa Decarboxylase Inhibitor
Objective: To evaluate the safety, tolerability, levodopa pharmacokinetics, and exploratory efficacy of TR-012001 in Parkinson’s disease (PD). Background: TR-012001 is a novel investigational prefilled nasal…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 62
- Next Page »